Endocrine Abstracts

It has been suggested that the selective m-TOR inhibitor, Rapamycin, has been improved the success pancreatic islet allotransplantation (ITx) in type 1 diabetic patients (T1DM). Forty-one ITx were studied. Thirteen T1DM in poor glycemic control underwent a 45-days Rapamycin before ITx followed by standard Edmonton Protocol (EP, group 1, Milan), and they were compared to 28 T1DM patients undergoing EP (group 2, Miami). Outcome measures were daily insulin requirement (DIR), HbA1...